Trial Profile
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY OF THE EFFICACY AND SAFETY OF TOFACITINIB IN SUBJECTS WITH ACTIVE ANKYLOSING SPONDYLITIS (AS)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jan 2024
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 15 Nov 2023 Results of Post hoc analysis of pooled data from NCT01786668 and NCT03502616 trials presented at the ACR Convergence 2023.
- 03 Jun 2023 Results of pooled hoc analysis (n=269) assessing the median time to improvement of pain, morning stiffness and disease activity in tofacitinib-treated pts with AS presented at the 24th Annual Congress of the European League Against Rheumatism
- 03 Jun 2023 Results of pooled post hoc analysis (n=372 from studies NCT01786668 and NCT03502616) assessing the impact of BL CRP levels on tofacitinib efficacy and safety in pts with AS presented at the 24th Annual Congress of the European League Against Rheumatism